Dr. Judith Reichman 'Today' show contributor • Profile • E-mail

Choosing to take estrogen during menopause is one of the more confusing decisions a woman has to make, with some studies linking it to heart disease and other studies saying it can help prevent heart disease. "Today" contributor and gynecologist Dr. Judith Reichman sheds some light on the issue:

We see the ads, hear the statistics, and even wear red to acknowledge that heart attack and strokes are the leading causes of death in women. In a public health effort to overcome our ongoing female cardiac and brain complacency, we have been exhorted to take charge and:

• Not smoke
• Exercise
• Not gain weight
• Treat high blood pressure
• Lower cholesterol

But what about hormones?

Here's a look at why estrogen, taken in early menopause, may actually help prevent coronary heart disease (CHD), whereas taking it years later may not. 

Why the hormonal confusion?
Many of our early studies showed that estrogen prevents heart disease; then along came others that demonstrated that hormone replacement in menopause could increase the risk of heart attack and stroke. The earlier “positive” studies were observational; women who took estrogen were followed and compared to women who did not. Those on high doses of the most commonly prescribed form of estrogen, Premarin (1.25 to 2.5 milligrams a day) had a 50 to 70 percent reduction of CHD. When doses were reduced and progestin added (to protect the uterine lining from cancerous changes), the benefit was still there, but “only” 30 percent. The argument was subsequently made that part of the so-called estrogen benefit came not from taking the hormone but from the fact that women who took it were initially healthier and had a higher socioeconomic status than nonusers. There is some justification for this, however, when the statisticians corrected for these factors, the observed heart benefits of estrogen persisted. 

We also know that in women who undergo removal of their ovaries before menopause and do not take estrogen replacement, the risk of heart attack increases dramatically; the younger they are at time of surgery, the higher the risk.  Even if a woman’s ovaries are removed in the years just prior to or at the beginning of menopause (50 to 59), lack of estrogen replacement may cause her to be twice as likely to develop atherosclerosis as a woman who has not undergone surgical menopause.  When women of the same age but different menopausal status are compared (one menopausal, the other, not) the menopausal woman has a two to threefold increase in her future risk of CHD.  In the final analysis: for each year’s delay in menopause, the risk of CHD decreases by 2 percent.

Scientists also like to demonstrate medical conditions and therapies in “controlled” experimental settings. And they have in monkeys — those who have been estrogen deprived as a result of the surgical removal of their ovaries develop atherosclerosis; when given estrogen replacement, the rapid plaque deposition in their arteries does not occur.

The paradox: What about those well known studies that show that hormone replacement can increase the risk of CHD? 
The HERS (the Heart and Estrogen/Progesterone Replacement Study) looked at nearly 3,000 women who already had significant heart disease. Their average age was 67.  When Premarin and synthetic progestin (MPA or Provera) was given to half of these women, they had more heart attacks during the first year of therapy than the control women who took no hormones. But when the hormone-treated women were followed for an additional four to five years, there was a late benefit: they had fewer heart attacks and strokes than the controls. The study was then continued for two more years (the HERS II trial), at which time hormone replacement did not seem to make a difference (heart attacks and strokes were the same in both groups).

The Women’s Health Initiative (WHI) seemed to corroborate these findings. This was a huge trial designed to evaluate hormone therapy in over 16,000 theoretically healthy women who had not undergone hysterectomy. They were randomly divided into two groups: One was given Prempro (a combination of Premarin and Provera) and the other a placebo. The average age of these women was 63 and many were 12 or more years past their menopause transition.  The majority of women were overweight or obese (a cause for underlying atherosclerosis) and few had significant menopausal symptoms of hot flashes or night sweats. After less than five years — amidst much media attention — the trial was halted.  The treated women had an increased rate of heart attack, stroke, pulmonary embolism, and clots in the deep veins, as well as an increase in the incidence of breast cancer. But there was some good news, the treated women had fewer osteoporotic fractures and were less likely to develop colon cancer.

Was it the Premarin (Prem) or the Provera (Pro) that was to blame for some of these risks?
Possibly it was the Provera. If you add Provera to Premarin when treating female monkeys whose ovaries have been removed, the Provera opposes the ability of the estrogen to limit plaque formation in the arteries. Natural types of progesterones have not been found to have this negative effect. In studies in female humans (not just monkeys), researches have found that Premarin and other estrogens lower bad cholesterol (LDL), increase good cholesterol (HDL), and improve the ability of vessels to dilate so blood flow is facilitated. Provera blunts these cardiovascular benefits. 

And while we’re discussing side effects of hormone replacement, let’s go to the issue of breast cancer. A separate part of the WHI as well as other studies have demonstrated that estrogen therapy alone does not seem to increase risk for breast cancer. The risk appears to increase only with added progestin exposure.

Prempro was the hormone used in these studies. Are other hormones safer? 
There are many alternative estrogens that are FDA approved for treatment of menopausal symptoms. Most are composed of estradiol (the estrogen made by our ovaries) and are plant-derived. Estrogen can be delivered through the skin as a patch (products include Climara and Vivelle) and as a gel or a skin emulsion (EstroGel and Estrosorb).  It can also be absorbed into the body through the vagina (Fem Ring). Several types of progestins that are more like that which our ovary makes (progesterone) are also plant-derived. Prometrium is an FDA-approved formulation of progesterone. It has not been found to blunt the positive effects of estrogen on the vessels in the heart.

Only on TODAY.MSNBc.com! Dr. Judith Reichman addresses your questions about women's health. LAST WEEK: Will removing my ovaries prevent cancer? GO TO ALL HEALTH TUESDAY COLUMNS

There may be a difference in side effects depending on whether estrogen enters the body in pill form or via patches, gels or rings. (I know the latter sounds weird; no we are not discussing jewelry!) Many researchers feel that oral estrogen pills or capsules, which pass through the gastrointestinal tract, are immediately metabolized in the liver where they increase factors that are pro-inflammatory. We now know that inflammation causes damage to blood vessels and increases the risk of heart attack and stroke. One such inflammatory factor is called C-reactive protein (CRP) which, when found to be elevated in women is correlated with an increased risk of these cardiovascular events. It’s possible that the higher incidence of CHD in the first years of the HERS and WHI trials was partially due to an increase in inflammatory factors. Switching to non-oral estrogens that go through the skin or vagina will, to some extent, bypass this initial effect on the liver, and may reduce this inflammatory “insult."

When it comes to progestin, doctors are trying to figure out how to diminish its effect on breast tissue. Lower and lower doses are now prescribed and progestins that are considered “heart healthy” are often used. Some form of progestin is usually given to protect the uterine lining, but it should achieve this goal when given every few months for 12 to 14 days. Progesterone can also be given as a vaginal gel called Prochieve. There are physicians who, after discussions with their patients, don’t prescribe progestin at all and simply monitor the uterine lining with pelvic ultrasound and/or endometrial biopsies. Obviously women who have had a hysterectomy do not need any form of progestin. 

Print this Email this Blog this  IM this

MORE FROM HEALTH

Health Section Front

You’re not crazy, but you might need therapy   28 million women face unwanted pregnancy Group fears step taken toward ‘designer babies’ Overeater sheds 240 pounds — naturally Lose 10 pounds in 6 weeks! It’s easy Oh, baby: The year’s most popular names Think all salads are healthy? Think again Make smart snacking choices on the go Treat your feet! An owner’s guide for the sole Got a big bottom? A reason to be glad Health Section Front   Add Health headlines to your news reader: